A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - ScienceDirect
Muscle-invasive and Metastatic Bladder Cancer - DISEASE MANAGEMENT - Uroweb
Dose-Dense (DD)-MVAC for Bladder Cancer | ChemoExperts
Cancers | Free Full-Text | Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic ...
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study - Clinical Genitourinary Cancer
Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study | Scientific Reports
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - ScienceDirect
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO - ScienceDirect
Systemic Chemotherapy for Urothelial Cancer – How to Select Systemic Therapy in Bladder Cancer | touchONCOLOGY
Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | springermedizin.de
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia - Gurney - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
Dose dense MVAC prior to radical cystectomy: a real-world experience | SpringerLink
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Approved checkpoint inhibitors in bladder cancer: which drug should be used when? - Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack, 2018
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Page 1
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer | Nature Reviews Urology
Understanding Systemic Chemotherapy Options in Bladder Cancer Part II: Chemotherapy Candidacy & Side Effects
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy | Journal of Urology
1616-Bladder/Urothelial neoad ddMVAC (dd methotrexate vinBLASTine DOXOrubicin ciSplatin) | eviQ
Page 1
